Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

The 22% weight loss reported in the study ... in the company’s approved obesity med Wegovy, with another engineered peptide called cagrilintide. Novo Nordisk last month reported this once ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase ... (20 mg versus 2.4 mg for Wegovy) of this more complex ...

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

CagriSema demonstrated a significantly greater body weight loss in obese participants ... According to Novo Nordisk, more than 25,000 new people start taking Wegovy every week, further ...

Novo Nordisk's stock (NVO ... The new drug, amycretin, similar to the company's blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, provided weight loss of up to 22% in early-stage ...